Gut and respiratory microbiota landscapes in IgA nephropathy: a cross-sectional studyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study mapped the gut and respiratory microbiota in IgA nephropathy (IgAN), a kidney disease tied to mucosal immunity. It aimed to find site-specific bacteria and build diagnostic models. Researchers collected stool samples and pharyngeal throat swabs, then used 16S rRNA sequencing to compare patients with healthy controls. Machine-learning algorithms (random forest, SVM, CART, XGBoost) classified IgAN from microbial differences. Spearman correlation linked key bacteria to clinical parameters and treatment status.
Who was studied?
The cross-sectional study enrolled 87 patients with biopsy-confirmed primary IgAN and age- and sex-matched healthy controls at a hospital in Shanxi, China. It ran from December 2021 to December 2022. Stool samples came from 61 IgAN patients and 68 controls. Throat swabs came from 87 patients and 94 controls, with 60 individuals providing both. Patients were split into pre-medication (n = 66) and post-immunosuppressive-therapy (n = 21) groups. IgAN patients had elevated creatinine and urea and reduced filtration rate.
What were the most important findings?
Both gut and respiratory microbiota showed reduced diversity in IgAN, with lower Chao1 and Shannon indices. Beta diversity separated patients from controls (gut PERMANOVA p = 0.021, respiratory p = 0.001). Machine-learning models classified IgAN well. For gut microbiota, random forest reached 83.33% accuracy and an AUC of 0.855. For respiratory microbiota, XGBoost reached 95.56% accuracy, 100% specificity, and an AUC of 0.99. Two taxa were shared across both gut and respiratory sites and correlated with clinical severity. Immunosuppressive therapy shifted specific gut and respiratory taxa, including reduced Neisseria in the respiratory tract.
What are the greatest implications of this study?
The study suggests gut and respiratory microbial signatures could support noninvasive diagnosis of IgA nephropathy, currently confirmed only by kidney biopsy. Respiratory microbiota gave the strongest classification. Shared bacteria at both mucosal sites, correlating with proteinuria, creatinine, and disease stage, may inform the mucosal-immunity basis of IgAN. Treatment altered microbial structure, hinting at monitoring value. The design was cross-sectional at a single center with a modest sample, so it shows association, not causation. The authors plan larger studies to validate these microbial markers.